This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Amarin Insiders Rush to Sell Stock One Day After Fish-Oil Pill Approval

Updated with new information about the timing of Amarin insider stock sale plans.

BEDMINSTER, NJ ( TheStreet) -- Six Amarin (AMRN - Get Report) insiders sold company stock valued at more than $12 million on July 27 -- one day after U.S. regulators approved the prescription fish-oil pill Vascepa.

The timing of the Amarin insider sales -- led by CEO Joe Zakrzewski ($2.2 million), President John Thero ($4.3 million) and Director Carl Gordon ($5.4 million representing his investment fund Orbimed Advisors) -- are likely to trigger alarm bells for ordinary investors trying to figure out the future direction of the company.

Abingworth Corp., a London-based investment fund, also disclosed Monday night the sale of almost 2 million shares of Amarin on July 19. The sale reduces Abingworth's stake in Amarin to 5.6% from 6.9%.

Amarin shares are down 7% to $11.86 in early trading.

The FDA approval of Vascepa on July 26 was a major victory for Amarin, so it's not necessarily surprising to see company insiders reward themselves for hard work done well. But Amarin still faces important, unsettled issues regarding Vascepa. The FDA's decision on the length of market exclusivity, or New Chemical Entity (NCE) status, is still pending, and Amarin hasn't yet announced how it plans to sell Vascepa.

Investors don't like unsettled issues, which is one reason why Amarin's stock price has fallen 17% since Vascepa's approval was announced on July 26. The decision by Amarin insiders to quickly cash out large chunks of their holdings -- even if done under the legal cover of pre-scheduled 10b5-1 trading plans -- just adds another layer of worry on top.

Amarin President Thero set up his 10b5-1 trading plan on June 13, according to a regulatory filing. That's just nine days before top Amarin executives and its lawyers met with FDA officials and the agency's lawyers for an "Orange Book discussion" -- presumably to discuss the NCE status of Vascepa. A high-level meeting like this doesn't occur spontaneously, so it's possible, even highly likely, Thero knew about the reasons for the meeting when he set up his 10b5-1 plan.

Likewise, Amarin CEO Zakrzrewski set up his 10b5-1 plan on May 9, according to a regulatory filing.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AMRN $2.38 1.50%
VVUS $2.36 -4.10%
YHOO $44.13 -0.69%
AAPL $124.25 -0.14%
FB $81.66 -0.68%

Markets

DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs